AstraZeneca delivers 5.3 million doses of COVID-19 vaccine to Thailand during July

Press Releases »

AstraZeneca confirmed that it delivered 5.3 million doses of its COVID-19 vaccine to the Ministry of Public Health during July, as part of an ongoing commitment to deliver 61 million doses to Thailand as quickly as possible.

AstraZeneca delivers 5.3 million doses of COVID-19 vaccine to Thailand during July

The July deliveries meet AstraZeneca's projections which show that in months with uninterrupted manufacturing, the company can supply between five and six million doses to Thailand. AstraZeneca delivers 5.3 million doses of COVID-19 vaccine to Thailand during July

As of the end of July, AstraZeneca has delivered a total of 11.3 million doses of its COVID-19 vaccine to Thailand, and the company has started delivering to nearby countries from its Thailand supply chain.

James Teague, Country President, AstraZeneca (Thailand) Ltd., said: "Our partner Siam Bioscience is performing amongst the strongest in our worldwide manufacturing network, operating at full capacity and delivering to the highest quality standards. Where possible, we will collaborate with them to deliver vaccines faster. We are proud to be working with Siam Bioscience and helping to bring the people of Thailand on the path to recovery as quickly as possible by supporting the country's mass vaccination program."

The vaccine is around 80%-90% effective against severe disease and hospitalisation and is highly effective against all variants of concern, including beta and delta.1,2 Overall safety is comparable to other vaccines.3 Very rare thrombotic events can be treated with early diagnosis and there is no increased risk of very rare thrombotic events after the second dose.4,5

AstraZeneca continues to supply its COVID-19 vaccine globally at no profit during the pandemic period.


ข่าวAstraZeneca+the companyวันนี้

AstraZeneca and the Faculty of Pharmaceutical Sciences, Chulalongkorn University, have signed an MOU to announce their collaboration in enhancing the potential of pharmaceutical personnel

This includes offering learning opportunities through practical experience and co-developing a curriculum that facilitates access to innovative medicines, thereby strengthening a robust and sustainable public health system. AstraZeneca Thailand and the Faculty of Pharmaceutical Sciences at Chulalongkorn University announce a strategic collaboration formalised through the signing of a Memorandum of Understanding (MOU) to enhance the potential of students and company personnel through various

AstraZeneca Thailand, in collaboration wi... AstraZeneca Thailand Launches NCD Certification Programme to Enhance Chronic Disease Care — AstraZeneca Thailand, in collaboration with the General Practi...

AstraZeneca's long-acting antibody (LAAB) combination granted conditional marketing approval for the treatment of COVID-19 in Thailand

AstraZeneca's AZD7442 (tixagevimab and cilgavimab), a long-acting antibody combination (LAAB), has been granted conditional marketing approval in Thailand for the...